Get the app
US › Healthcare

Evaxion Biotech AS (EVAX)

US · Healthcare · Biotechnology

$2.83+1.07%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-3.7M
EPS
$-0.50
EPS estimate
$-0.01

EPS came in at -0.50 against a street estimate of -0.01 — a miss of 4900.0%.

Key statistics

Market cap
$25.3M
Forward P/E
3.6
P/B
3.10
Book value
$1.14
EPS (TTM)
$-1.03
52-week high
$9.50
52-week low
$2.72
50-day MA
$3.14
200-day MA
$3.60
Beta
0.51

Analyst view

Analysts rate Evaxion Biotech AS a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $11.25.

Shareholding

Insiders
16.15%
Institutions
9.42%

Largest institutional holders

FundStake
Merck & Co Inc13.46%
Ikarian Capital, LLC0.83%
Rathbone Brothers PLC0.51%
Citadel Advisors Llc0.41%
Renaissance Technologies Corp0.37%
Annis Gardner Whiting Capital Advisors LLC0.33%
J. Safra Sarasin Holding AG0.25%
Rhumbline Advisers0.24%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Evaxion Biotech AS — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.